About Genprex
Genprex is a company based in Austin (United States) founded in 2009.. Genprex has raised $3.11 million across 9 funding rounds from investors including NIH and Inception Capital Management. The company has 15 employees as of December 31, 2024. Genprex offers products and services including Oncoprex® Delivery System, Reqorsa® Gene Therapy, and GPX-002. Genprex operates in a competitive market with competitors including Insulet, Kriya Therapeutics, Sana Biotechnology, Poseida Therapeutics and Semma Therapeutics, among others.
- Headquarter Austin, United States
- Employees 15 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Genprex, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-21.11 M31.59as on Dec 31, 2024
-
EBITDA
$-21.17 M31.85as on Dec 31, 2024
-
Total Equity Funding
$3.11 M (USD)
in 9 rounds
-
Latest Funding Round
$2.59 M (USD), Grant
Jul 21, 2020
-
Investors
NIH
& 1 more
-
Employee Count
15
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Genprex
Genprex is a publicly listed company on the NASDAQ with ticker symbol GNPX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Genprex
Genprex offers a comprehensive portfolio of products and services, including Oncoprex® Delivery System, Reqorsa® Gene Therapy, and GPX-002. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
System for delivering genes to treat cancer effectively
Therapy reintroducing genes to suppress tumors in patients
Treatment targeting cancer and diabetes through gene administration
Unlock access to complete
Unlock access to complete
Funding Insights of Genprex
Genprex has successfully raised a total of $3.11M across 9 strategic funding rounds. The most recent funding activity was a Grant round of $2.59 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Grant — $2.6M
-
First Round
First Round
(20 Dec 2013)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2020 | Amount | Grant - Genprex | Valuation |
investors |
|
| May, 2020 | Amount | Post-IPO - Genprex | Valuation |
investors |
|
| Feb, 2020 | Amount | Post-IPO - Genprex | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Genprex
Genprex has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH and Inception Capital Management. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investments are directed toward US and Australia opportunities.
|
Founded Year | Domain | Location | |
|
Drug discovery services are provided to the biopharma sector.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Genprex
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Genprex
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Genprex Comparisons
Competitors of Genprex
Genprex operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insulet, Kriya Therapeutics, Sana Biotechnology, Poseida Therapeutics and Semma Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Wearable insulin infusion systems are developed for diabetes patients.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| domain | founded_year | HQ Location |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment
|
|
| domain | founded_year | HQ Location |
Cell-based therapies for cancer treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Genprex
Frequently Asked Questions about Genprex
When was Genprex founded?
Genprex was founded in 2009 and raised its 1st funding round 4 years after it was founded.
Where is Genprex located?
Genprex is headquartered in Austin, United States. It is registered at Austin, Texas, United States.
Is Genprex a funded company?
Genprex is a funded company, having raised a total of $3.11M across 9 funding rounds to date. The company's 1st funding round was a Post-IPO of $17.5M, raised on Dec 20, 2013.
How many employees does Genprex have?
As of Dec 31, 2024, the latest employee count at Genprex is 15.
What does Genprex do?
Founded in 2009 and based in Austin, United States, operations in the biotechnology sector are focused on cancer therapeutics. Molecular-level treatments, including the lead candidate Oncoprex combined with erlotinib, are designed to induce apoptosis in cancer cells and regulate signaling and inflammatory pathways. These therapies target non-small cell lung cancer and metastases, with delivery via injection.
Who are the top competitors of Genprex?
Genprex's top competitors include Insulet, Senti Biosciences and Sana Biotechnology.
What products or services does Genprex offer?
Genprex offers Oncoprex® Delivery System, Reqorsa® Gene Therapy, and GPX-002.
Is Genprex publicly traded?
Yes, Genprex is publicly traded on NASDAQ under the ticker symbol GNPX.
Who are Genprex's investors?
Genprex has 2 investors. Key investors include NIH, and Inception Capital Management.
What is Genprex's ticker symbol?
The ticker symbol of Genprex is GNPX on NASDAQ.